A Phase 1 interventional study of AZD3366 and Placebo in Cardiovascular Disease, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-18.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single intravenous (IV) ascending doses.
Part B of this study is a randomized, single-blind, parallel group placebo-controlled study to assess the safety, tolerability and PD of a single IV administration of AZD3366 with concomitant loading doses followed by repeated maintenance dosing of ticagrelor and acetylsalicylic acid (ASA).
The study will provide data on safety, tolerability, PK, and PD of AZD3366 in healthy subjects. Three populations (healthy subjects, healthy Japanese subjects and healthy Chinese subjects) will be enrolled into this study.
This study will be conducted at a single study center in United States of America (USA).
Part A of the study will investigate the safety, tolerability, PK, and PD (inhibition of platelet aggregation and capillary bleeding time [CBT]) of an IV administration of single ascending doses (SAD) of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects.
Part B of the study will investigate the safety, tolerability, and PD (inhibition of platelet aggregation and CBT) of a single IV dose of AZD3366 or placebo with concomitant administration of ticagrelor and ASA by a parallel group cohort consisting of of healthy subjects. Furthermore, the potential effect of AZD3366 on the PK of ticagrelor will be investigated. Co-medication with ASA and ticagrelor is chosen based on the Standard of Care anti-platelet treatment regimen in patients with myocardial infarction.
5,370 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.
This study's enrollment of 103 is close to the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females must have a negative pregnancy test at Screening and on admission to the study center, must not be lactating, and must be of non-childbearing potential, confirmed at Screening, by fulfilling one of the below criteria:
Exclusion Criteria:
Subjects having history of the following are excluded:
Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results, coagulation parameters, including but not limited to the list below:
Any abnormal vital signs, after 10 minutes supine rest, as defined in the list below, at the Screening Visit and/or Day -1:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized healthy subjects will receive Dose 1 of AZD3366.
Drug: AZD3366
Randomized healthy subjects will receive Dose 2 of AZD3366.
Drug: AZD3366
Randomized healthy subjects will receive Dose 3 of AZD3366.
Drug: AZD3366
Randomized healthy subjects will receive Dose 4 of AZD3366.
Drug: AZD3366
Randomized healthy subjects and healthy Japanese subjects will receive Dose 5 of AZD3366.
Drug: AZD3366
Randomized healthy subjects and healthy Japanese subjects will receive Dose 6 of AZD3366.
Drug: AZD3366
Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Dose 7 of AZD3366.
Drug: AZD3366
Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Placebo matched to AZD3366.
Drug: Placebo
Randomized healthy subjects will receive Dose X of AZD3366 in conjunction with concomitant administration of ticagrelor and ASA.
Drug: AZD3366 · Drug: Ticagrelor · Drug: acetylsalicylic acid (ASA)
Randomized healthy subjects will receive Dose X of placebo in conjunction with concomitant administration of ticagrelor and ASA.
Drug: Placebo · Drug: Ticagrelor · Drug: acetylsalicylic acid (ASA)
In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
In Part B, subjects will receive oral ticagrelor tablets.
Also known as: Brilinta
In Part B, subjects will receive oral ASA chewable tablets.
Also known as: Chewable aspirin
Number of subjects with adverse events and serious adverse events in both Part A and Part B
Adverse events will be assessed to investigate the safety and tolerability of intravenous administration of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects.
Time frame: From screening (Day -21) to follow-up (Day 60 for Part A and Day 50 for Part B)
Area under plasma concentration-time curve from time zero extrapolated to infinity (AUCinf) to characterize the PK of AZD3366 in Part A
To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.
Time frame: Pre-dose, and post-dose (Day 1 to Day 60)
Terminal half life (t½λz), estimated as (ln2)/λz to characterize the PK of AZD3366 in Part A
To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.
Time frame: Pre-dose, and post-dose (Day 1 to Day 60)
Total body clearance of drug from plasma after intravascular administration (CL) to characterize the PK of AZD3366 in Part A
To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.
Time frame: Pre-dose, and post-dose (Day 1 to Day 60)
Volume of distribution at steady state from a systemic dose (Vss) to characterize the PK of AZD3366 in Part A
To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.
Time frame: Pre-dose, and post-dose (Day 1 to Day 60)
Area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUClast) to characterize the PK of AZD3366 in Part A
To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.
Time frame: Pre-dose, and post-dose (Day 1 to Day 60)
Area under the plasma concentration-time curve from time zero to 48 hours after dosing [AUC(0-48)] to characterize the PK of AZD3366 in Part A
To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.
Time frame: Pre-dose, and post-dose (Day 1 to Day 60)
Observed maximum plasma concentration (Cmax) to characterize the PK of AZD3366 in Part A
To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.
Time frame: Pre-dose, and post-dose (Day 1 to Day 60)
Time to reach peak or maximum observed concentration following drug administration (tmax) to characterize the PK of AZD3366 in Part A
To characterize the PK of AZD3366 following IV administration of single doses of AZD3366 in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.
Time frame: Pre-dose, and post-dose (Day 1 to Day 60)
To study the platelet aggregration of AZD3366 in Part A
To study platelet aggregation by Light Transmision Aggregometry (LTA) in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.
Time frame: Pre-dose, and post-dose (Day 1 to Day 60)
Assessment of the duration of capillary bleeding time (CBT) to characterize the PD of AZD3366 in Part A
To characterize the PD of AZD3366 following IV administration of single doses of AZD3366 with respect to inhibition of CBT in healthy subjects, healthy Japanese subjects and healthy Chinese subjects in Part A.
Time frame: Pre-dose and post-dose (Day 1)
Collection of blood samples for the analyses of antidrug antibodies (ADAs) in both Part A and Part B
To explore immunogenicity following IV administration of AZD3366 in both Part A and Part B.
Time frame: At Day -1, Day 15, Day 23 and Day 44 in Part A, and pre-dose (Day 1), Day 15, Day 29 and Day 50 in Part B
Collection of blood samples for adenosine diphosphate-induced associated periodic-induced platelet aggregation in platelet-rich plasma to characterize the PD of AZD3366 in Part B
To study the plasma exposure and characterize the PD of AZD3366 with respect to inhibition of platelet aggregation LTA, following IV administration of AZD3366 at one dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)
Collection of blood samples for tumor necrosis factor receptor associated periodic-induced platelet aggregation in platelet-rich plasma to characterize the PD of AZD3366 in Part B
To study the plasma exposure and characterize the PD of AZD3366 with respect to inhibition of platelet aggregation LTA, following IV administration of AZD3366 at one dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)
CBT to characterize the PD of AZD3366 in Part B
To study the PD (inhibition of CBT) of AZD3366 at 1 dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.
Time frame: Pre- dose and post-dose (Day 1 and Day 3)
AUClast to characterize the plasma exposure and PD of AZD3366 in Part B
To study the plasma exposure, and PD (inhibition of platelet aggregation and CBT) of AZD3366 at 1 dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)
AUC(0-48) to characterize the plasma exposure and PD of AZD3366 in Part B
To study the plasma exposure, and PD (inhibition of platelet aggregation and CBT) of AZD3366 at 1 dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)
Cmax to characterize the plasma exposure and PD of AZD3366 in Part B
To study the plasma exposure, and PD (inhibition of platelet aggregation and CBT) of AZD3366 at 1 dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)
tmax to characterize the plasma exposure and PD of AZD3366 in Part B
To study the plasma exposure, and PD (inhibition of platelet aggregation and CBT) of AZD3366 at 1 dose level in healthy subjects with concomitant loading dose and repeated dosing of ticagrelor and ASA in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3, Day 15, Day 29, and Day 50)
AUCinf to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B
To study the effect of AZD3366 on the PK of ticagrelor in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3)
AUClast to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B
To study the effect of AZD3366 on the PK of ticagrelor in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3)
tmax to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B
To study the effect of AZD3366 on the PK of ticagrelor in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3)
t½λz to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B
To study the effect of AZD3366 on the PK of ticagrelor in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3)
Area under the plasma concentration-time curve from time zero to 12 hours after dosing [AUC(0-12)] to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B
To study the effect of AZD3366 on the PK of ticagrelor in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3)
Cmax to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B
To study the effect of AZD3366 on the PK of ticagrelor in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3)
Observed trough plasma concentration after the first dose (Ctrough) to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B
To study the effect of AZD3366 on the PK of ticagrelor in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3)
Arithmetic mean of plasma concentration (C) at 12, 24, 36 and 48 hrs post-dose [Cmean (12, 24, 36, 48 hrs)] to characterize the PK of ticagrelor and ticagrelor active metabolite, AR-C124910XX in Part B
To study the effect of AZD3366 on the PK of ticagrelor in Part B.
Time frame: Pre-dose and post-dose (Day 1 to Day 3)
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please re-refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Ran from Oct 2020 to primary completion in Jan 2022, 15 months.
Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 15 months is above that.
Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ticagrelor · Aspirin